The Real 'Negotiation' In HR3: Framing The Pricing Debate
Executive Summary
First hearing on the House leadership’s drug price “negotiation” proposal suggests that the real goal of the plan may be to shape negotiations over drug pricing bills – not to create an international price benchmark.
You may also be interested in...
Drug Pricing Legislation In The US May Be Losing Momentum
House subcommittee hearing on drug price negotiation bill championed by Speaker Nancy Pelosi showcases strong Republican opposition, and Senate Finance Committee Chairman Chuck Grassley suggests his bill may not be ready for a floor vote until next year.
Part D Out-Of-Pocket Cap Would Be $2,000 In House Drug Pricing Bill
It may seem perverse to look for silver linings for the drug industry in the House leaderships “price negotiation” bill. But if you can get past Title 1, the bill reads like an attempt to negotiate with the Senate Finance Committee – and it’s not all bad.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.